Skip to content

A study on the efficacy of Remimazolam in preventing and treating emergence agitation after sevoflurane inhalation anesthesia

A study on the efficacy of Remimazolam in preventing and treating emergence agitation after sevoflurane inhalation anesthesia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110857
Enrollment
Unknown
Registered
2025-10-21
Start date
2023-07-03
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence agitation

Interventions

Group Remidazolam:Remidazolam
Group Dexmedetomidine:Dexmedetomidine

Sponsors

Li Huili Hospital, Ningbo Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing general anesthesia for otolaryngology surgery. 2.ASA I~II. 3.Age 18-65. 4.Patients without obvious abnormalities in preoperative blood routine, liver and kidney function, electrolytes and coagulation function. 5.Patients signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with severe past psychiatric history and intellectual disability who cannot cooperate with treatment 2.Alcohol dependence, long-term use of psychotropic drugs, identification / suspicion of narcotic sedative analgesic abusers 3.Obese patients with BMI >= 30 kg/m ^2 4.Patients with bradycardia (sinus bradycardia<55 times) and atrioventricular block of degree II or above 5.Left bundle branch block 6.Cardiac function class III and above 7.Those who are allergic to experimental drugs and other related drugs

Design outcomes

Primary

MeasureTime frame
Sedation Agitation Scale;

Secondary

MeasureTime frame
Mean arterial pressure;Heart rate;Duration of anesthesia;Anesthesia awakening time;Extubation time;PACU stay time;Visual analogue score;

Countries

China

Contacts

Public ContactZhang Ying

Li Huili Hospital, Ningbo Medical Center

370604962@qq.com+86 176 2186 7426

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026